CureVac AG, the Germany-based developer of messenger RNA (mRNA) therapies, has created a new division for rare diseases and hired Alan Kimura, an experienced pharma executive, to lead it. Dr Kimura was most recently chief medical officer at Enzyvant, a developer of drugs for rare diseases. He also held senior positions at the vaccine company SutroVax Inc and Translate Bio, an mRNA therapeutics company.
Dr Kimura received a medical degree from the University of Miami School of Medicine and and a PhD in microbiology from the University of California-Davis, US.
CureVac announced the appointment on 26 February 2020.
Copyright 2020 Evernow Publishing Ltd